1. Home
  2. PATH vs PRAX Comparison

PATH vs PRAX Comparison

Compare PATH & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UiPath Inc.

PATH

UiPath Inc.

SELL

Current Price

$12.39

Market Cap

7.3B

Sector

Technology

ML Signal

SELL

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

SELL

Current Price

$305.32

Market Cap

7.1B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PATH
PRAX
Founded
2005
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3B
7.1B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
PATH
PRAX
Price
$12.39
$305.32
Analyst Decision
Hold
Strong Buy
Analyst Count
20
19
Target Price
$15.41
★ $674.48
AVG Volume (30 Days)
★ 22.4M
436.3K
Earning Date
12-03-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 500.00
N/A
EPS
★ 0.11
N/A
Revenue
★ $1,610,572,000.00
N/A
Revenue This Year
$11.28
N/A
Revenue Next Year
$8.25
$55,143.56
P/E Ratio
$119.55
★ N/A
Revenue Growth
★ 12.65
N/A
52 Week Low
$9.20
$160.11
52 Week High
$19.84
$392.70

Technical Indicators

Market Signals
Indicator
PATH
PRAX
Relative Strength Index (RSI) 39.17 52.18
Support Level $10.58 $281.96
Resistance Level $13.33 $349.73
Average True Range (ATR) 0.49 19.86
MACD -0.05 3.54
Stochastic Oscillator 8.92 45.96

Price Performance

Historical Comparison
PATH
PRAX

About PATH UiPath Inc.

UiPath Inc offers an end-to-end cross-application enterprise automation platform principally with computer vision technology and user interface automations in its initial RPA offering, which remains the foundation of the platform. The platform leverages a range of automation technologies, including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries, including claims processing, employee onboarding, invoice-to-cash, loan applications, and customer service. The company works in the Americas, Europe, the Middle East, and Africa, and Asia-Pacific, with the maximum revenue from the America.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: